Medical Affairs — the function that translates clinical evidence for physicians, payers, and regulators — has been demonstrating its value for decades. The problem is not evidence. It is power.

Most biotech leaders understand that launch preparation, building the plan, begins well before expected approval. That's not the problem we see.

Strategic planning within a company must be interconnected, with a clear hierarchy that aligns every effort with the overarching vision and mission.

A well-informed asset strategy is an essential component of developing a novel therapy to meet critical patient needs.